NervGen Pharma Grants 545,000 Stock Options to Employees and Consultants

NervGen Pharma ( (TSE:NGEN) ) has shared an update.

NervGen Pharma has granted 545,000 incentive stock options to its employees and consultants, with specific allocations to company officers and investor relations consultants. This move aligns with the company’s stock option plan and TSX Venture Exchange policies, potentially enhancing employee motivation and aligning interests with company growth objectives.

More about NervGen Pharma

NervGen Pharma is a clinical-stage biotech company focused on developing neurorestorative therapeutics. It aims to promote nervous system repair in cases of neurotrauma and neurologic disease. The company is currently testing its lead molecule, NVG-291, in a Phase 1b/2a clinical trial for spinal cord injury and is also evaluating a new candidate, NVG-300, for ischemic stroke, ALS, and spinal cord injury.

YTD Price Performance: -17.97%

Average Trading Volume: 62,087

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $136.3M

For detailed information about NGEN stock, go to TipRanks’ Stock Analysis page.